Welcome to Ophthalmic Trials Australia

Ophthalmic Trials Australia (OTA) is one of Australia’s leading private ophthalmic clinical research sites, with particular expertise in anterior eye disease and Phase I, II and III clinical trials.

OTA has evolved from more than two decades of clinical optometry and specialist anterior eye care through Mark Hinds Optometrists, combined with many years of dedicated clinical trial experience across investigational pharmaceuticals, biologics, devices and other ophthalmic technologies.

Our clinical and research focus has placed OTA at the forefront of studies involving dry eye disease, ocular surface disease, ocular pain, corneal disease, keratoconus, glaucoma and other anterior segment conditions. Our team has extensive experience delivering early-phase and proof-of-concept research, including first-in-human and Phase I programs, through to Phase II and Phase III clinical development.

The strength of OTA lies not only in its clinical trial infrastructure, but also in the depth of its multidisciplinary team. Our investigators and clinical staff include subspecialist ophthalmologists, medical practitioners, ophthalmology registrars, nurses and highly experienced optometrists, bringing together complementary expertise across ophthalmic disease, clinical assessment, study conduct and patient management.

Our investigators also contribute beyond site-based trial delivery. Members of the OTA team sit on multiple scientific advisory boards and have extensive experience contributing to clinical trial design, protocol development, study construct, endpoint selection and broader clinical development strategy. This involvement extends into early commercial and translational discussions, including engagement with biotechnology companies, industry stakeholders and venture capital groups considering the clinical and commercial development of emerging ophthalmic technologies.

This combination of long-standing clinical practice and dedicated research infrastructure gives OTA direct access to a highly characterised and continually expanding database of more than 35,000 patients. Developed over decades of clinical care, professional networking and referral relationships, this patient population represents a broad range of ages, ethnicities, genetic backgrounds, disease phenotypes and lifestyles.

Our established collaboration with both private and public ophthalmology further extends our clinical reach and provides access to specialist expertise, referral pathways and diverse patient populations across a wide spectrum of ophthalmic disease.

OTA also maintains strong working relationships with leading ophthalmology-focused and global clinical research organisations (CROs). These relationships, together with our experience working directly with biotechnology, pharmaceutical and medical-device companies, allow our team to integrate efficiently with sponsors, medical monitors, project managers, data-management teams and international clinical operations groups throughout the development pathway.

At the centre of OTA is a commitment to conducting high-quality, rigorous, ethical and efficient clinical research. Our objective is to help sponsors safely and effectively progress innovative investigational therapies, devices and technologies from early clinical development through later-phase evaluation and, ultimately, toward clinical use.

Our research history includes ongoing collaborations with industry, academic institutions, clinicians and research partners, together with contributions to scientific presentations and peer-reviewed publications. Just as importantly, many sponsors and research partners have returned to OTA with subsequent programs, reflecting the strength of the working relationships, recruitment capability, clinical expertise and trial delivery developed by our team.

Over the years, we have built a valued international network of sponsors, CROs, investigators, scientific advisers and collaborators united by a common objective: to advance ophthalmic research, protect sight and improve quality of life for patients with eye disease.

We welcome opportunities to collaborate with organisations developing the next generation of ophthalmic therapeutics, devices and technologies.